

Amendments to the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application, wherein additions are shown in underlined text and deletions are shown in strike-out text:

Claim 1 (Currently Amended) A method of treating an individual ~~suffering from chronic pain associated with~~ peripheral neuropathy, the method comprising ~~the step of~~ administering to the an individual ~~a therapeutically effective amount of~~ in need of treatment optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount to treat such chronic pain.

Claim 2 (Previously Presented) The method of claim 1 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.1 to about 10 mg/day.

Claim 3 (Previously Presented) The method of claim 2 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 8 mg/day.

Claim 4 (Previously Presented) The method of claim 3 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg/day.

Claim 5 (Previously Presented) The method of claim 4 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim 6 (Previously Presented) The method of claim 5 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim 7 (Previously Presented) The method of claim 6 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim 8 (Previously Presented) The method of claim 7 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim 9 (Previously Presented) The method of claim 1 wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim 10 (Original) The method of claim 9 wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim 11 (Original) The method of claim 10 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim 12 (Previously Presented) The method of claim 9 wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

Claim 13 (Canceled).

Claim 14 (Previously Presented) The method of claim 1 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim 15 (Currently Amended) The method of claim 1 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claim 16 (Currently Amended) The method of claim 15 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claim 17 (Currently Amended) The method of claim 16 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claims 18-67 (Cancelled).